Irving Investors — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Metagenomimetagenomi.coin𝕏Jan 2022 · $175M
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.
BiotechDeep TechMedical DevicesBerkeley, US
Brian Thomas(Executive Officer, Director, Promoter)in
BoardAndrew Farquharson(Director)inJak Knowles(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent CapitalFrazier Life SciencesHumboldt+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.